Form 8-K

8-K — Scienture Holdings, Inc.

Accession: 0001493152-26-047579

Filed: 2026-10-19

Period: 2026-10-13

CIK: 0001382574

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001382574

2026-10-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): October 13, 2026

SCIENTURE

HOLDINGS, INC.

(Exact

Name of Registrant as Specified in Its Charter)

Delaware

001-39199

46-3673928

(State

or other jurisdiction

incorporation)

(Commission

File

No.)

(I.R.S.

Employer

Identification

No.)

Austin Blvd.

Commack,

NY 11725

(Address

of Principal Executive Offices)

(631)

670-6039

(Registrant’s

Telephone Number)

Not

Applicable

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock, par value $0.00001 per share

SCNX

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

October 13, 2026, Scienture Holdings, Inc. issued a press release announcing certain preliminary financial results for the quarter ending

September 30, 2026, and other recent operational highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current

Report on Form 8-K and is incorporated herein by reference.

The

information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject

to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933,

as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item

3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

previously disclosed, on October 14, 2025, Scienture Holdings, Inc. (the “Company”) received a written notice

from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”)

indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”),

as the minimum bid price of the Common Stock had been below $1.00 per share for 30 consecutive business days. In accordance with Nasdaq

Listing Rule 5810(c)(3)(A), the Company was provided an initial compliance period of 180 calendar days, or until April 14, 2026, to regain

compliance with the Minimum Bid Price Requirement. The Company subsequently was provided an additional 180 calendar day compliance period,

or until October 12, 2026, to regain compliance with the Minimum Bid Price Requirement.

October 19, 2026, the Company received written notice from the Staff stating Nasdaq has determined that the closing bid price of the

Company’s shares of common stock was at least $1.00 per share for the ten consecutive trading days between October 5, 2026 and

October 16, 2026 (the “Compliance Notice”). Accordingly, the Company has regained compliance with the Minimum

Bid Price Requirement.

Prior

to receiving the Compliance Notice, the Company received a determination letter from the Staff notifying the Company that it had not

regained compliance with the Minimum Bid Price as of the end of the second compliance period on October 12, 2026. However, the Company

subsequently regained compliance with the Minimum Bid Price Requirement as confirmed in the Compliance Notice. As a result, Nasdaq has

determined that this matter is now closed and the Company’s securities will remain listed for trading on Nasdaq.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated October 13, 2026.

104

Cover

Page Interactive Data File (embedded with the Inline XBRL document).

Forward

Looking Statements

This

Current Report on Form 8-K contains certain statements that may be deemed to be “forward-looking statements” within the federal

securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are

not historical are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange.

Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements

are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our

beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our management team’s

expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those

products may have in the marketplace, such as Arbli™ and REZENOPY™, and our strategies related to those products. In addition,

any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying

assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,”

“believe,” “continue,” “could,” “estimate,” “expect,” “intend,”

“may,” “ongoing,” “plan,” “potential,” “predict,” “project,”

“should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that

a statement is not forward-looking. These statements are based on our expectations and involve risks, uncertainties and other important

factors that could cause our actual results performance or achievements (or entities in which we have an interest), or industry results,

to differ materially from future results, performance or achievements expressed or implied by such forward-looking statements. Certain

factors that could cause our actual future results to differ materially from those discussed are noted in connection with such statements,

but other unanticipated factors (including those beyond our control) could arise. Certain risks regarding our forward-looking statements

are discussed in our filings with the Securities and Exchange Commission, including an extensive discussion of these risks in our Annual

Report on Form 10-K for the year ending December 31, 2025, as amended, and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned

not to place undue reliance on these forward-looking statements which reflect management’s view only as of the date of this Current

Report on Form 8-K. We undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events

or circumstances after the date hereof or to reflect the occurrence of unanticipated events, conditions or circumstances.

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

SCIENTURE

HOLDINGS, INC.

By:

/s/

Dr. Narasimhan Mani

Dr.

Narasimhan Mani

Co-Chief

Executive Officer

Date:

October 19, 2026

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Continued

Arbli™ sales growth, combined with REZENOPY™ commercial launch in August 2026

and initial wholesale

shipments, drives significant sequential revenue growth

Arbli™

wholesale unit sales increased 74% sequentially, with recent institutional formulary

additions supporting continued commercial expansion

COMMACK,

NY, Oct. 13, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for

existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through

the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced preliminary,

unaudited revenue of approximately $1.22 million for the third quarter ended September 30, 2026, representing an increase of 256% compared

to approximately $344,000 in the second quarter of 2026.

The

substantial sequential increase in preliminary revenue reflects the successful commercial launch of REZENOPY™ and initial

wholesale shipments, as well as continued sales growth and increasing market adoption of Arbli™. These results mark

an important milestone in Scienture’s commercial expansion, reflecting the addition of a second FDA-approved product and continued

progress toward building a diversified, multi-product pharmaceutical portfolio.

“These

preliminary third-quarter revenue results mark a significant inflection point for Scienture, demonstrating the accelerating commercial

momentum of our expanding pharmaceutical portfolio,” said Narasimhan Mani, President and Co-Chief Executive Officer of Scienture

Holdings. “With Arbli™ continuing to gain traction and REZENOPY™ becoming our second commercial-stage

product following its August 2026 launch, we believe Scienture is well-positioned to meaningfully accelerate top-line revenue growth

through the remainder of 2026 and into 2027. As we work to expand our distribution channels and drive commercial adoption, we believe

our historically high gross margins will provide significant operating leverage, supporting our goal of achieving profitability in 2027.”

“Our

preliminary third-quarter revenues reflect the progress we have made in executing our commercial strategy and establishing Scienture

as a growing specialty pharmaceutical company,” said Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture

Holdings. “Looking ahead, we see significant opportunities to further penetrate our addressable markets, particularly as we focus

on increasing institutional adoption, expanding healthcare provider engagement and entering strategic commercial partnerships. With two

differentiated FDA-approved products addressing important unmet needs commercialized, we believe Scienture is well-positioned to build

a sustainable, high-value pharmaceutical business and deliver long-term value to shareholders.”

The preliminary revenue figures described in this press release are unaudited and subject to customary adjustments. The Company’s

full financial results for Q3 2026 will be included in a Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission

in accordance with federal securities rules and regulations.

About

Arbli™

is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first

and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf

life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than

six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic

nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™

provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™

provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded

losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

Arbli™

is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle

as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the

date of manufacture when stored at room temperature.

INDICATION

Arbli™

is an angiotensin II receptor blocker (ARB) indicated for:

● Treatment

of hypertension, to lower blood pressure in adults and children greater than 6 years old.

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily

strokes and myocardial infarctions.

● Reduction

of the risk of stroke in patients with hypertension and left ventricular hypertrophy.

● Treatment

of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with

type 2 diabetes and a history of hypertension.

IMPORTANT

SAFETY INFORMATION

● Do

not take Arbli™ when pregnant. When pregnancy is detected, discontinue Arbli™

as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury

and death to the developing fetus. Arbli™ can cause fetal harm when

administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during

the second and third trimesters of pregnancy reduces fetal renal function and increases fetal

and neonatal morbidity and death.

● Do

not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid

use of aliskiren with Arbli™ in patients with renal impairment (GFR <60 mL/min).

● Do

not administer Arbli™ in patients with severe hepatic impairment. Arbli™

has not been studied in patients with severe hepatic impairment.

● The

most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness,

upper respiratory infection, nasal congestion, and back pain.

You

are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also contact Scienture at 1-833-754-4917.

Please

see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.

About

Hypertension

(high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According

to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million

people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher.

Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk

of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and

drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic

blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.

About

REZENOPY™

(naloxone hydrochloride) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid

overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate

administration as emergency therapy in settings where opioids may be present.

REZENOPY™

nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.

IMPORTANT

SAFETY INFORMATION

REZENOPY™

(naloxone hydrochloride) Nasal Spray 10 mg is an opioid antagonist indicated for the emergency treatment of known or suspected opioid

overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate

administration as emergency therapy in settings where opioids may be present and is not a substitute for emergency medical care.

Important

Safety Information

● Contraindications:

REZENOPY™ nasal spray is contraindicated in patients known to be hypersensitive

to naloxone hydrochloride or to any of the other ingredients.

● Warnings

and Precautions:

● Risk

of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative

to the opioid, keep the patient under continued surveillance and administer additional doses

as necessary while awaiting emergency medical assistance.

● Risk

of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory

depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine

and pentazocine, may be incomplete. Larger or repeat doses may be required.

● Precipitation

of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid

withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and

properly treated. Monitor for the development of opioid withdrawal.

● Risk

of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result

in adverse cardiovascular effects. These events have primarily occurred in patients who had

pre-existing cardiovascular disorders or received other drugs that may have similar adverse

cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting

after use of naloxone hydrochloride.

● Adverse

Reactions: The following adverse reactions were observed in a REZENOPY™

nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia.

For

complete product information, including Patient Information, please refer to the full Prescribing Information.

About

Scienture Holdings, Inc.

SCIENTURE

HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company

focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market

needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals

who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare

systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and

channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary

Statements Regarding Forward-Looking Statements

This

press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities

laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical

are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange

Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking

statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry,

our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management

team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the

success those products may have in the marketplace, such as Arbli™ and REZENOPY™, and our strategies

related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events

or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking

statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,”

“expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,”

“project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words

does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties

(some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or

implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These

risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of

such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain

of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Stock Market LLC; claims relating to

alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings

that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed

in our most recent Annual Report on Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission.

Forward-looking

statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking

statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided

by law.

Contact:

SCIENTURE

HOLDINGS, INC.

20 Austin Blvd

Commack, NY 11725

Email: IR@Scienture.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Oct. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 13, 2026

Entity File Number

001-39199

Entity Registrant Name

SCIENTURE

HOLDINGS, INC.

Entity Central Index Key

0001382574

Entity Tax Identification Number

46-3673928

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Austin Blvd.

Entity Address, City or Town

Commack

Entity Address, State or Province

Entity Address, Postal Zip Code

11725

City Area Code

(631)

Local Phone Number

670-6039

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock, par value $0.00001 per share

Trading Symbol

SCNX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Entity Information, Former Legal or Registered Name

Not

Applicable

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Former Legal or Registered Name of an entity

+ References

No definition available.

+ Details

Name:

dei_EntityInformationFormerLegalOrRegisteredName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration